Activities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 546-551

  Bermudez, Luiz E ^a   Inderlied, Clark B ^b   Kolonoski, Peter ^a   Wu, Martin ^a   Barbara Burnham, Lucia ^b   Young, Lowell S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; ETHAMBUTOL; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030048688     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.546     Document Type: Article

References (32)

1. Amsterdam, D. 1991. Susceptibility testing of antimicrobial agents in liquid medium, p. 53-105 In V. Lorian (ed.). Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore.
2. Bermudez, L. E., and C. B. Inderlied. Unpublished data
3. Bermudez, L. E., M. Wu, L. Barbara-Burnham, P. Kolonoski, C. B. Inderlied, and L. S. Young. 1994. Anti-M. avium effect of Bay Y 3118 in vitro and in vivo, abstr. 828 In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Bertram, M. A., C. B. Inderlied, S. Yadegar, P. Kolonoski, J. K. Yamada, and L. S. Young. 1986. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J. Infect. Dis. 154:194-195.
5. Bongaerts, G. P. A., and J. A. A. Hoogkamp-Korstange. 1993. In vitro activities of Bay Y 3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrob. Agents Chemother 37:2017-2019.
6. Chiu, J., J. Nussbaum, S. Bozzette, J. G. Tilles, L. S. Young, J. Leedom, P. N. R. Hesseltine, J. A. McCutchan, and California Collaborative Treatment Group. 1990. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin Ann. Intern. Med 113:358-361.
7. Dautzenberg, B., C. Truffot, S. Legris, M. C. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, and J. Grosset. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am. Rev Respir. Dis. 144:564-569.
8. Fernandes, P. B., D. J. Hardy, D. McDaniel, C. W. Hanson, and R. N. Swanson. 1989 In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother 33:1531-1536.
9. Fu, K. P., S. C. LaFredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Topia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin). an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
10. Gangadharam, P. R., C. K. Edwards III, P. S. Murthy, and P. F. Pratt. 1983. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am. Rev. Respir. Dis. 127:648-649.
11. Garcia, I., A. Pascual, and E. J. Perea. 1994 Intracellular penetration and activity of Bay Y 3118 in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother 38:2426-2429.
12. Garrelts, J. C. 1991. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. Ann. Pharmacol. 25:525-531.
13. Heifets, L. B., and P. J. Lindholm-Lery. 1987. Bacteriostatic and bactericidal activities of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 68:267-276.
14. Inderlied, C. B., L. Barbara-Burnham, M. Wu, L. S. Young, and L. E. Bermudez. 1994. Activity of benzoxazinorifamycin-KRM 1648 against Mycobacterium avium complex in the beige mouse Antimicrob. Agents Chemother. 38:1838-1843.
15. Inderlied, C. B., P. T. Kolonoski, M. Wu, and L. S. Young. 1989. In vitro and in vivo activity of azithromycin (CP 62, 993) against the Mycobacterium avium complex. J. Infect Dis. 159:994-997.
16. Inderlied, C. B., L. S. Young, and J. K. Yamada. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimicrobial agents by various methods. Antimicrob. Agents Chemother. 31:1697-1702.
17. Jacobson, M. A., D. Yajko, E. Northfelt, et al. 1992. Randomized, placebocontrolled trial of combined rifampin (RIF), ethambutol (EMB), ciprofloxacin (CIPRO) therapy (Rx) for disseminated M. avium complex (DMAC) infection, abstr. 895. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1324-1328.
19. Kaatz, G. W., S. M. Leo, and C. A. Ruble. 1993. Efflux-mediated fluroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094
20. Kemper, C. A., D. Havlir, D. Haghighat, M. Dube, A. E. Bartok, J. P. Sison, Y. Yao, B. Yangco, J. M. Leedom, J. G. Tilles, J. A. McCutchan, and S. C. Deresinski. 1994. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS J. Infect. Dis. 170:157-164.
21. Kemper, C. A., M. Tze-Chiang, J. Nussbaum, J. Chiu, D. F. Feigal, A. E. Bartok, J. M. Leedom, J. G. Tilles, S. C. Derezinski, A. McCutchan, and California Collaborative Treatment Group. 1992 Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann. Intern. Med. 116:466-472.
22. Klemens, S. P., and M. H. Cynamon. 1991 In vivo activities of newer rifamycin analogs against Mycobacterium avium infection Antimicrob. Agents Chemother. 35:2026-2030
23. Mor, N., J. Vanderkolk, and L. Heifets. 1994. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 38:1161-1164.
24. Nichterlein, T., M. Kretschmar, C. Budeanu, J. Bauer, W. Linss, and H. Hof. 1994. Bay Y 3118, a new quinolone, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob. Agents Chemother. 38:1501-1506.
25. Rastogi, N., and V. Labrousse. 1991. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex Antimicrob. Agents Chemother 35:462-470
26. Skinner, P. S., S. K. Furney, D. A. Kleinert, and I. M. Orme. 1995. Comparison of activities of fluroquinolones in murine macrophages infected with Mycobactenum tuberculosis. Antimicrob. Agents Chemother. 39:750-753
27. Tomioka, H., K. Sato, H. Saito, and Y. Yamada. 1989 Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antimicrobial drugs. Microbiol. Immunol. 33:509-514.
28. Tsukamura, M., E. Nakamura, S. Yoshii, and S. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis Am. Rev. Resp. Dis. 131:144-148.
29. Yajko, D. M., C. A. Sanders, P. S. Nassos, and W. K. Hadley. 1990. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin and comparison with ciprofloxacin. Antimicrob. Agents Chemother. 34:2442-2444.
30. Young, L. S., O. G. Berlin, and C. B. Inderlied. 1987. Activity of ciprofloxacin and other flourinated quinolones against mycobacteria. Am J Med. 82:23-26.
31. Young, L. S., L. Wiviott, M. Wu, P. T. Kolonoski, R. Bolan, and C. B. Inderlied. 1991. Azithromycin reduces Mycobacterium avium complex bacteremia and relieves the symptoms of disseminated disease in patients with AIDS. Lancet 338:1107-1109.
32. Young, L. S., M. Wu, J. Bender, and a. S. S. group. 1992. Pilot study of sparfloxacin for M avium complex (MAC) bacteremia complicating AIDS, abstr 897. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.